GFAP and Alzheimer disease: As shown in Figure 6J, compared with the empty vector, the upregulation of PANK2 contributed to decreased levels of Aβ and GFAP, both of which are AD pathological features, suggesting that PANK2 plays a positive role in AD treatment, while the mechanism through which PANK2 reduces AD biomarkers still requires further exploration.